Geneva, Nov. 3 -- International Clinical Trials Registry received information related to the study (ISRCTN16355728) titled 'OM336 in seropositive autoimmune diseases' on Oct. 22.
Study Type: Interventional
Study Design:
Open-label multicenter multiple-ascending-dose study (Treatment, Safety)
Primary Sponsor: Ouro Medicines Ltd.
Condition:
Sjogren's Disease (SjD), Idiopathic Inflammatory Myopathy (IIM)
Musculoskeletal Diseases
Intervention:
Generic drug name / active substance:
OM336 (INN pending
recombinant humanized bispecific antibody directed at BCMA and CD3).
Treatment Arms
OM336 is administered in 3 multiple ascending dose (MAD) cohorts and 3 expansion cohorts as summarized below:
Cohorts / Treatment Arms:
* Cohort A1: 5...